Guardian Unlimited
Go to:  
Guardian UnlimitedThe Guardian
Home UK Business Online World dispatch The wrap Weblog Talk Search
The Guardian World News guide Arts Special reports Columnists Audio Help Quiz

UK news
 
  Search this site








  In this section
Drugs for depressed children banned

Climate change doubles Britain's stormy weather

Broadmoor lets out woman, 94, after 40 years

BBC 'skimped' on Clark diaries

Child poverty adverts banned

Ofsted pins literacy blame on weak teaching

Loyalist bombers 'helped by British'

Police appeal to mothers over attack on jogger

In brief

Japanese car maker faces strike

Monsters that turned turtle

Police failed over killing, says tycoon

Woman held as police hunt Calvi killers

Atkins diet may curb epilepsy

Osbourne still on ventilator

Bookings slump for Faliraki

Sir Stephen Tumim dies at 73

Jamaica joins Met to tackle drug gangs

Previous offenders

Fishing protest leaves booze cruisers stranded

Thames Trains pleads guilty over Paddington

Huntley admits girls' manslaughter

Mother cleared of infant sons' deaths

Brown: borrowing hike 'within golden rule'


Drugs for depressed children banned

Sarah Boseley, health editor
Wednesday December 10, 2003
The Guardian


Modern antidepressant drugs which have made billions for the pharmaceutical industry will be banned from use in children today because of evidence, suppressed for years, that they can cause young patients to become suicidal.

The Medicines and Healthcare Products Regulatory Agency (MHRA) told doctors last night not to prescribe all but one of the antidepressants known as selective serotonin reuptake inhibitors (SSRIs).

The exception is Prozac, which is licensed for use in depressed children in the US. But the MHRA will warn that, at best, it helps only one child in 10.

The decision has big implications for drug regulation.

The agency - which is the government's watchdog body on drug safety - has reached this point only after intense pressure from patients and campaigners.

They were concerned about patients - at first mainly adults - who appeared to have become suicidal on the drugs, and others who had got hooked and suffered distressing symptoms when they tried to stop taking them.

Public unease about these potential side-effects prompted the agency to investigate last year. It has looked at the details of clinical trials of depressed children that were in the hands of the drug companies in the late 1990s. These studiesrevealed the problem of suicidal behaviour in children, but the companies did not draw it to the attention of the regulators in the US or the UK.

It has become clear from the investigation that the regulators generally see only a summary of the data resulting from trials. It is prepared for them by the drug company only when it is seeking a licence.

The agency became aware of a problem with Seroxat in children this year only when the manufacturer, GlaxoSmithKline, submitted data from trials which finished in 1996.

Pressure for a change in the regulatory system will inevitably grow.

Two of the SSRI class of drugs have already been banned - or, technically, contra-indicated in children - by the agency.

The first, in June, was Seroxat, which goes by the generic name paroxetine; the second, in September, was Efexor (venlafaxine); joining them now will be Lustral (sertraline), Cipramil (citalopram), Cipralex (escitalopram) and Faverin (fluvoxamine).

Trials on children have not been carried out in all the drugs, but the completed studies show a worrying increase in suicidal behaviour among those on SSRIs compared with those given a placebo (sugar pill).

None of the drugs has a licence for use in children with depression in the UK, but GPs have prescribed more and more SSRIs for children.

It is estimated that as many as 50,000 children on antidepressants in Britain.

The agency will warn that patients should not stop their medication suddenly to avoid withdrawal symptoms.

The ban will cause problems for doctors because insufficient counsellors and psychotherapists are available to offer the alternative treatment of therapy, and the bill to the NHS for such treatment would be much higher than the cost of the drug prescriptions.

Drug companies began clinical trials on the safety and efficacy of the SSRIs in children only after prompting by the US food and drug administration in the early 90s.

David Healy, the director of the North Wales department of psychological medicine, said: "It was standard practice for the FDA approving drugs like Seroxat (Paxil in the US) for adults in 1991 to write to the company and say this drug will also be used in children - it would be helpful if you could run trials in children so we can see what the safety profile is."

But trials that did not produce favourable results were neither published nor sent to the FDA or the MHRA.

The first major Seroxat trial in children was finished by 1996, but the results were not published until 2001. Data was also gathered in 1996 after a trial of Lustral, manufactured by Pfizer, showing that 9% of depressed children on the drug became suicidal.

Dr Healy, whose own researches led to the establishment of the SSRI review, said yesterday: "They should have known by 1996 that there was a problem. GSK and Pfizer were asked to do this by the regulators so that we knew what the safety issues were."

The drug companies dispute that a problem exists. Only a tiny minority of children taking the drug become suicidal and their depression could be the real cause, they claim. GSK says several trials, not just one, were needed to establish whether its drug caused problems.

The SSRI review group, which has advised the Committee on the Safety of Medicines of the agency to ban the drugs from use in children, will now look at the safety and efficacy of the drugs in adults.

Special reports
Medicine and health

Useful links
British Medical Association
Department of Health
General Medical Council
Health on the Net Foundation
Institute of Cancer Research
Medical Research Council
NHS Direct
World Health Organisation




Printable version | Send it to a friend | Save story

 
 



UP

Guardian Unlimited Guardian Newspapers Limited 2003